Lam Research Corporation vs Organon & Co. Common Stock — how do they compare? Lam Research Corporation trades at $279.07 (market cap $359.06B), while Organon & Co. Common Stock trades at $13.73 (market cap $3.61B). The key difference: Lam Research Corporation is far larger — about 99.5× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays the higher dividend (0.58%). Which is the better fit depends on your goals — on Pluang, investors hold Lam Research Corporation for 61 Days and Organon & Co. Common Stock for 0 Days on average.
| LRCX | OGN | |
|---|---|---|
Market Cap | $359.06B | $3.61B |
Volume | 10,336,294 | 1,808,049 |
Sector | Technology | Health |
52-Week High | $433.33 | $13.81 |
52-Week Low | $139.59 | $5.70 |
Typical Hold Time | 61 Days | 0 Days |
Enterprise Value | $357.21B | $11.03B |
Dividend Yield | 0.46% | 0.58% |
Signals from Pluang's Aura AI — not financial advice
Lam Research (LRCX) trades at $301.11, down 2.73% on the day, amid a bearish technical signal but strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $18.44B in 2025, with a net income margin of 31.27% and robust cash flow from operations of $6.17B. Analyst sentiment remains overwhelmingly positive, with a consensus price target of $375.68.
LRCX presents a compelling long-term opportunity driven by AI-driven semiconductor equipment demand, though near-term technical weakness and high valuation multiples pose risks. The company's strategic positioning in advanced chip manufacturing supports growth, but investors should monitor execution against earnings expectations and competitive dynamics in the semiconductor equipment sector.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Lam Research manufactures equipment used to fabricate semiconductors. The firm is focused on the etching, deposition, and clean markets, which are key steps in the semiconductor manufacturing process, especially for 3D NAND flash storage, advanced DRAM, and leading-edge logic/foundry chipmakers. Lam's flagship Kiyo, Vector, and Sabre products are sold in all major geographies to key customers such as Samsung Electronics, Micron, Intel, and Taiwan Semiconductor Manufacturing.
Read more on LRCX →Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →